Johnson & Johnson to Acquire TARIS Biomedical for its Drug Delivery Technology to Treat Bladder Cancer

 Johnson & Johnson to Acquire TARIS Biomedical for its Drug Delivery Technology to Treat Bladder Cancer

Johnson & Johnson to Acquire Auris Health for its Monarch Technology for $5.7B

Shots:

  • J&J acquires TARIS Biomedical while TARIS to continue research in Lexington, Massachusetts and will also become part of Janssen R&D’s Oncology Therapeutic Area. Additionally, the companies will focus on optimization of drug candidates for advancing and delivering future clinical programs utilizing TARIS technology
  • The focus of an acquisition is to utilize TARIS’ drug delivery technology for advancing TAR-200 candidate further strengthening targeted oncologic therapy approach
  • TARIS’ TAR-200 is an investigational candidate designed to release chemotherapeutic agent gemcitabine continuously in bladder for multiple weeks and has also received FDA’s Fast Track Designation in patients with organ-confined or locally advanced MIBC who are unfit for curative-intent therapy

Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post